NT5E and neoplasm: In tumor models, the combination of anti-CD73 and anti-PD-1 antibodies exhibited synergistic effectiveness against ADO-driven immunosuppression, prompting a phase I trial of anti-CD73 in cancer patients (NCT02503774) (198).